Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A £210,000 donation from the Alan Davidson Foundation has been made to our Department to advance our world-leading research into Motor Neuron Disease. The funding will support a project manager to deliver an innovative research project using the genetic causes of MND to develop approaches to early diagnosis.

Alan Davidson with dog and letter

MND symptoms develop insidiously and the early stages can be similar to other conditions, which means that diagnosis can sometimes take a year or more. As a result, damage to the nervous system can go undetected before physical symptoms become apparent. Professor Talbot and his research group work as part of the Oxford Motor Neuron Disease Centre, linking the research to clinical care.

The team has already established promising approaches to treatment in patients who currently have the disease. The aim of this new ground-breaking research is to identify people at risk of MND before symptoms occur, so that treatment can be applied at the early stages when it can be more effective and disability can be prevented.

About 10 per cent of patients with MND have a genetic mutation and each of their close relatives (parents, siblings and children) will have a 50 per cent chance of carrying the gene that leads to MND. The research funded by ADF will sign up 300–400 'at risk' individuals, who will be carefully monitored to enable the team to pick up the very earliest signals of the disease. The ultimate aim is to produce a blood test that could be used in general practice to screen for the silent damage occurring in the early phase of MND. A cohort study of this kind, linking in with the established MND network, will be unique, and once the cohort is in place, major research funding will also be sought to analyse the samples donated by people taking part in the study.

I remember Alan vividly. He was an exceptional individual who achieved great things in his life and his enquiring mind lives on in the foundation's commitment to MND research. This pioneering new project aims to understand the very earliest changes that occur, before physical symptoms progress. In the longer term it will contribute towards our aim of making MND a preventable condition.
- Professor Kevin Talbot

Alan Hayes Davidson RIBA was a Scottish architectural visualiser who pioneered the use of computers to create realistic digital images of buildings. Having started his career as an architect, he founded the world-leading visualisation studio Hayes Davidson in 1989 to pursue his interest in computer modelling, making it the first company dedicated to producing computer-generated imagery for the architecture industry. The studio was commissioned to illustrate many well-known and iconic London buildings before they were built or extended, including the London Eye, the Tate Modern, the Millennium Dome (now the O2), the Royal Academy, the Royal Festival Hall and the British Museum.

Alan was diagnosed with MND in 2012 and the Alan Davidson Foundation was set up in 2015, three years before his death at the age of 58. He committed the majority of his estate to good causes through the foundation, including MND research.

Caite Healy, ADF Trustee and friend of Alan, says: 'During his own illness, Alan was hugely helped by understanding the in-depth science behind the treatment options. When he set up the Alan Davidson Foundation, he wanted his legacy to support innovative science and new ideas. We know he would have been hugely enthusiastic about this exciting project and what it aims to achieve.'

Make a Gift

If you would like to make a gift to the Oxford Motor Neuron Disease Centre, please visit the University of Oxford Development Office donation page.

Similar stories

Attention and memory deficits persist for months after recovery from mild COVID

Researchers from Oxford’s Nuffield Department of Clinical Neurosciences and Department of Experimental Psychology have shown that people who have had COVID but don’t complain of long COVID symptoms in daily life nevertheless can show degraded attention and memory for up to six to nine months.

New Academic Visitor from Nigeria

Associate Professor of Radiology, Godwin Ogbole has arrived on a six-month visit to the Nuffield Department of Clinical Neurosciences, as part of the Africa Oxford Initiative.

New spinout company: Human-Centric Drug Discovery

Human-Centric Drug Discovery is a new Oxford University spinout company from Professor Zameel Cader's lab.

Research finds drug may benefit some patients hospitalised with COVID-19 pneumonia

A proof-of-concept trial involving Oxford researchers has identified a drug that may benefit some patients hospitalised with COVID-19 pneumonia.

Protein test could lead to earlier and better diagnosis of Parkinson’s

Scientists have observed the clumping of alpha-synuclein in the cerebrospinal fluid taken from people with Parkinson's. The findings offer hope that a pioneering new clinical test could be developed to diagnose Parkinson's correctly in its early stages.

Nine new Professors

Many congratulations to the following members of our Department who have been awarded the title of Professor in the recent Recognition of Distinction round.